Lilly's EloraTZP Beats Zepbound in Head-to-Head Obesity Trial
LLY sits 64% above its 52-week low of $725.31 on light trading volume (0.1× avg).
Summary
Lilly's experimental combination drug EloraTZP delivered 23.3% average weight loss over 48 weeks in a mid-stage trial, versus 14.8% for Zepbound, in patients with type 2 diabetes. The combo also cut A1C by up to 2.9% vs 2.4% for tirzepatide alone. Discontinuation rates were higher (10.8% to 27%) due to dual dose escalation, but the company plans to adjust escalation schedules in late-stage trials. This positions EloraTZP as a potential best-in-class obesity therapy, directly challenging Novo Nordisk's CagriSema, which is expected to launch early next year. Late-stage trials for EloraTZP are set to begin in Q4 2026.
At the time of this announcement, LLY was trading at $1,188.91 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $725.31 to $1,292.65. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Reuters.